Apixaban Dosing for Acute DVT
For this patient with acute DVT, the appropriate apixaban (Eliquis) dose is 10 mg orally twice daily for the first 7 days, followed by 5 mg twice daily thereafter—the standard treatment regimen without dose reduction. 1
Rationale for Standard Dosing
This patient does not qualify for dose reduction despite meeting some criteria that might initially suggest otherwise. Here's the critical distinction:
Dose Reduction Criteria Apply ONLY to Atrial Fibrillation
The dose reduction criteria (age ≥80 years, weight ≤60 kg [approximately 132 lbs], serum creatinine ≥1.5 mg/dL) apply exclusively to stroke prevention in atrial fibrillation, not to VTE treatment 2, 1. This patient:
- Is in her late 80s (meets age criterion)
- Weighs 118 pounds/53.6 kg (meets weight criterion)
- Has Cr 0.97 mg/dL (does NOT meet creatinine criterion)
However, these criteria are irrelevant for acute DVT treatment.
VTE Treatment Has No Pre-Specified Dose Reductions
For treatment of DVT/PE, apixaban has no pre-specified dose-reduction criteria based on age, weight, or renal function 3, 4. The FDA-approved regimen for acute VTE is uniform: 10 mg twice daily for 7 days, then 5 mg twice daily 1.
Renal Function Considerations
With a GFR of 53 mL/min (CKD Stage 3a), this patient has mild-to-moderate renal impairment. Importantly:
- Apixaban is safe in moderate renal impairment for VTE treatment without dose adjustment 4, 5
- Apixaban has the lowest renal clearance (approximately 25%) among DOACs, making it particularly suitable for patients with renal dysfunction 5
- No dose adjustment is recommended until CrCl falls below 15 mL/min 6
Treatment Regimen
Initial Phase (Days 1-7):
Maintenance Phase (Day 8 onward):
Extended Therapy (after 6 months, if indicated):
Common Pitfalls to Avoid
Do not inappropriately apply atrial fibrillation dose-reduction criteria to VTE treatment - This is the most common dosing error in clinical practice 8. Studies show that up to 60% of patients receiving reduced-dose apixaban do not meet appropriate criteria, often due to confusion between AF and VTE dosing guidelines.
Do not reduce dose based on age or weight alone in VTE - While this patient is elderly and underweight, these factors alone do not warrant dose reduction for acute DVT treatment 5, 1.
Do not use parenteral lead-in therapy - Unlike dabigatran and edoxaban, apixaban does not require initial heparin or LMWH 3, 4, 5. Starting with parenteral anticoagulation would be unnecessary and increase bleeding risk.
Monitoring Considerations
While routine laboratory monitoring is not required, this elderly patient with borderline renal function warrants:
- Periodic renal function assessment (every 3-6 months given CKD Stage 3a) 9, 6
- Assessment for bleeding risk factors
- Medication adherence evaluation
In rare circumstances requiring perioperative planning or suspected accumulation, apixaban-calibrated anti-Xa levels may be useful 10, though this is not routine practice.